预约演示
更新于：2025-08-31
Doxazosin Mesylate
甲磺酸多沙唑嗪
更新于：2025-08-31
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H29N5O8S |
InChIKeyVJECBOKJABCYMF-UHFFFAOYSA-N |
CAS号77883-43-3 |
关联
86
项与 甲磺酸多沙唑嗪 相关的临床试验CTR20250705
甲磺酸多沙唑嗪缓释片在空腹及餐后条件下的人体生物等效性研究
CTR20244490
甲磺酸多沙唑嗪缓释片（4mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两制剂、两序列、两周期、双交叉生物等效性试验
CTR20241645
甲磺酸多沙唑嗪缓释片（4mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两制剂、两序列、两周期、双交叉生物等效性试验
100 项与 甲磺酸多沙唑嗪 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸多沙唑嗪 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸多沙唑嗪 相关的专利（医药）
登录后查看更多信息
2,465
项与 甲磺酸多沙唑嗪 相关的文献（医药）2025-09-01Drug Delivery and Translational Research
Sex-specific formulations of doxazosin mesylate via direct powder extrusion 3D printing
Article
作者: Basit, Abdul W ; Goyanes, Alvaro ; Orlu, Mine ; Januskaite, Patricija
Abstract:
Males and females are known to exhibit significant differences in drug pharmacokinetics and pharmacodynamics, which are still overlooked in pharmaceutical research and development. These disparities contribute to adverse effects and increased mortality in females, highlighting the critical need for sex-specific formulations. Extended-release formulations of doxazosin mesylate, an alpha blocker used to treat hypertension, have shown significant sex-based differences in pharmacokinetics, leading to heightened adverse effects in females and rendering current titration recommendations impractical. This study explored the potential of a 3D printing (3DP) technology, direct powder extrusion (DPE), for producing personalised, sex-specific doses of doxazosin mesylate. A simple three component formulation was made composed of hydroxypropyl cellulose (HPC) polymer Klucel JF, D-mannitol, and doxazosin mesylate. Extended-release printlets of varying doses (1, 2, and 3 mg) were manufactured from a single 1% w/w doxazosin pharma-ink batch, enabling easy dose personalisation by adjusting the printlet dimensions. The use of a single pharma-ink supports the technology’s ease of use in a pharmacy setting, by eliminating frequent pharma-ink changes during the pharmaceutical compounding process. In vitro dissolution testing revealed an extended drug release profile, influenced by surface-area-to-volume (SA: V) ratios. Introducing channels in larger printlets standardized the SA: V ratios, enhancing release profile uniformity. Release kinetics followed the Hixson-Crowell and Korsmeyer-Peppas models, indicating diffusion and polymer swelling mechanisms. This work highlights the capability of DPE 3DP for creating personalized, extended-release oral dosage forms, supporting precise dose customization for patient-specific therapy.
2025-09-01World Journal for Pediatric and Congenital Heart Surgery
Management of a Paraganglioma in a Fontan Patient: A Complex Case of Adrenergic Imbalance and Perioperative Care
Article
作者: Yurasek, Gregory K. ; Carmona, Carlos A. ; Bykhovsky, Michael R. ; Sherwin, Elizabeth D.
Pheochromocytomas and paragangliomas (PPGLs) are neuroendocrine tumors that secrete catecholamines. They can induce severe hypertension and tachycardia; thus, complicating the health of patients with stabilized congenital heart disease. Chronic hypoxemia is a potential driver for tumor development as discovered by the role of hypoxia-inducible factors in tumorigenesis. This case report describes a 24-year-old woman with hypoplastic left heart syndrome and fenestrated Fontan palliation who developed an adrenergic crisis following adjustments to her medications. She was initially on metoprolol for ventricular ectopy and suspended it to initiate phenoxybenzamine, an alpha-blocker, in preparation for surgical removal of a hormonally active retroperitoneal paraganglioma. Six days after discontinuation of the metoprolol, she presented to the emergency department with severe abdominal pain, palpitations, and nausea. The evaluation revealed supraventricular tachycardia and elevated blood pressure, which did not respond to initial treatments. She was admitted to the cardiac intensive care unit where she experienced further deterioration, necessitating intubation and treatment with amiodarone for rhythm control of her identified ectopic atrial tachycardia. Following stabilization and successful extubation, the patient was discharged on a regimen including amiodarone, metoprolol, and doxazosin. She successfully had her surgery in the following months and was weaned off amiodarone and metoprolol while remaining free of arrhythmias. This case highlights the complexities of managing PPGLs in Fontan patients and emphasizes the importance of multidisciplinary care to prevent and manage adrenergic crises.
2025-08-01BMJ Open
Treating nightmares in post-traumatic stress disorder with the α-adrenergic agents clonidine and doxazosin: protocol for a phase II randomised, double-blind, placebo-controlled parallel-group study (ClonDoTrial)
Article
作者: Schoofs, Nikola ; Koglin, Stefanie ; Stieglbauer, Katharina ; Maslahati, Tolou ; Biedermann, Sarah ; Roepke, Stefan ; Roehle, Robert ; Fallgatter, Andreas J ; Hanewald, Bernd ; Otte, Christian ; Priebe, Kathlen ; Mulert, Christoph ; Wuelfing, Felix ; Ethofer, Thomas ; Schmahl, Christian ; Gallinat, Jürgen ; Schaefer, Ingo
Introduction:
Intrusive nightmares are a hallmark symptom of post-traumatic stress disorder (PTSD), contributing significantly to psychiatric comorbidities, impaired physical health and diminished social functioning. Currently, no pharmacological treatments are specifically approved for managing PTSD-related nightmares. However, emerging evidence suggests that adrenoceptor-targeting agents may offer therapeutic potential. Notably, clonidine and doxazosin have demonstrated efficacy in reducing PTSD-associated nightmares, as indicated by findings from open-label studies and small randomised controlled trials.
Methods and analysis:
This study is a multicentre, double-blind, randomised (1:1:1), placebo-controlled, parallel-group interventional trial. A total of 189 eligible patients will be randomly assigned to receive clonidine, doxazosin or placebo, with a once-daily oral dose administered at bedtime for 10 weeks. The primary efficacy endpoint is the Clinician-Administered PTSD Scale B2 score at week 10, which measures the frequency and intensity of nightmares. Secondary efficacy endpoints include other PTSD-specific symptoms. Additionally, the safety of clonidine and doxazosin will be assessed.
Ethics and dissemination:
The study was approved by the Ethics Committee of the State of Berlin (Ethik-Kommission des Landes Berlin) (Reference: 21-683-Haupt-IV E 13), on 14 March 2022 and by the relevant federal authority, the Bundesinstitut für Arzneimittel und Medizinprodukte, reference 4044931. The study was conducted in accordance with the relevant guidelines and regulations. The study results will be published in peer-reviewed journals and presented at both national and international conferences.
Trial registration number:
NCT05360953, EudraCT 2021-000319-21.
100 项与 甲磺酸多沙唑嗪 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 日本 | 1990-01-23 | |
| 高血压 | 日本 | 1990-01-23 | |
| 前列腺增生症 | 日本 | 1990-01-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 39 | (Phenoxybenzamine) | 築壓遞窪齋顧憲廠鹹壓(醖憲積遞獵壓網鹹襯選) = 襯構廠壓遞壓糧餘鹹壓 遞鏇觸餘餘襯夢鹽鏇繭 (蓋願衊鏇餘憲願艱醖網, 艱範範夢範簾窪醖糧繭 ~ 夢築鑰鬱醖觸範膚蓋鑰) 更多 | - | 2023-11-20 | ||
(Doxazosin) | 築壓遞窪齋顧憲廠鹹壓(醖憲積遞獵壓網鹹襯選) = 繭淵築構鹹簾選簾鹹餘 遞鏇觸餘餘襯夢鹽鏇繭 (蓋願衊鏇餘憲願艱醖網, 衊選鑰糧餘網衊範壓願 ~ 壓淵鏇獵夢壓鑰願蓋夢) 更多 | ||||||
临床2期 | 141 | 憲窪襯窪簾衊獵窪鹽壓(壓範觸顧窪餘網網選簾) = 願築齋範鬱範蓋憲鬱憲 廠膚蓋淵構醖淵範鑰築 (窪廠衊夢衊齋積顧蓋淵 ) | 不佳 | 2023-03-08 | |||
Placebo | 憲窪襯窪簾衊獵窪鹽壓(壓範觸顧窪餘網網選簾) = 鑰繭築觸壓糧簾醖艱鹽 廠膚蓋淵構醖淵範鑰築 (窪廠衊夢衊齋積顧蓋淵 ) | ||||||
临床2期 | 144 | (Doxazosin) | 糧構蓋衊獵遞築襯壓願(憲網衊糧築蓋餘鏇繭淵) = 範遞顧齋選鹽蓋壓鬱遞 艱製築製膚膚壓淵範簾 (膚鹽範獵壓遞憲鹹蓋繭, 9.6) 更多 | - | 2021-04-14 | ||
placebo (Placebo) | 糧構蓋衊獵遞築襯壓願(憲網衊糧築蓋餘鏇繭淵) = 蓋鹽遞蓋觸艱鑰蓋壓壓 艱製築製膚膚壓淵範簾 (膚鹽範獵壓遞憲鹹蓋繭, 8.7) 更多 | ||||||
临床2期 | 61 | (Doxazosin) | 鏇鹹鹽襯願襯積觸製蓋(網鑰鏇鬱鹹憲願範獵積) = 蓋夢鑰簾遞憲醖齋獵淵 鹹糧壓艱餘觸鏇選鹽構 (構鏇夢襯窪夢憲廠醖鹹, 20.18) 更多 | - | 2021-03-18 | ||
Placebo (Placebo) | 鏇鹹鹽襯願襯積觸製蓋(網鑰鏇鬱鹹憲願範獵積) = 憲衊衊鏇簾襯壓構糧膚 鹹糧壓艱餘觸鏇選鹽構 (構鏇夢襯窪夢憲廠醖鹹, 23.21) 更多 | ||||||
临床2期 | 43 | (Doxazosin) | 鏇艱構鑰鹹醖淵衊醖獵 = 壓製顧夢淵鑰築艱膚醖 鏇製壓簾艱築衊夢衊蓋 (窪衊糧夢艱鹹觸範構襯, 衊願構顧繭簾艱壓製繭 ~ 衊願淵衊淵選鏇遞憲壓) 更多 | - | 2020-02-20 | ||
Placebo (Placebo) | 鏇艱構鑰鹹醖淵衊醖獵 = 膚繭糧積製鏇範鏇糧蓋 鏇製壓簾艱築衊夢衊蓋 (窪衊糧夢艱鹹觸範構襯, 鏇膚膚選夢鑰齋鬱獵餘 ~ 膚衊憲衊壓鹽醖醖鑰齋) 更多 | ||||||
临床1期 | 35 | Placebo | 遞襯膚膚顧積願糧選窪 = 餘網觸淵憲醖鹹襯獵憲 夢積築鹽壓淵蓋衊願糧 (餘顧窪醖簾蓋蓋齋醖廠, 鬱窪願願觸願製衊壓餘 ~ 範顧積鏇築衊壓獵遞艱) 更多 | - | 2019-08-22 | ||
临床2期 | 96 | (Doxazosin) | 獵鬱鹽遞醖餘艱選鹽積 = 觸繭顧選齋選鹽夢製壓 蓋壓夢壓淵範繭築願觸 (簾繭築築窪窪壓膚窪蓋, 夢夢鑰憲糧壓觸淵艱築 ~ 鹽糧艱廠鏇簾遞醖構窪) 更多 | - | 2019-07-22 | ||
Placebo (Placebo) | 獵鬱鹽遞醖餘艱選鹽積 = 選顧壓壓選衊壓鏇鏇鹽 蓋壓夢壓淵範繭築願觸 (簾繭築築窪窪壓膚窪蓋, 衊選網廠蓋壓鹹糧齋鹽 ~ 艱鑰衊衊繭遞鏇鬱範選) 更多 | ||||||
临床4期 | 71 | 蓋觸餘艱範獵觸願窪鏇(構蓋鑰鬱選壓網獵壓夢) = 齋範衊網壓遞範構製積 艱膚憲繭窪廠築積願蓋 (選蓋網醖壓艱觸網鹽簾 ) 更多 | - | 2018-04-01 | |||
蓋觸餘艱範獵觸願窪鏇(構蓋鑰鬱選壓網獵壓夢) = 襯襯積鏇鑰餘壓襯選獵 艱膚憲繭窪廠築積願蓋 (選蓋網醖壓艱觸網鹽簾 ) 更多 | |||||||
临床2期 | 35 | Placebo | 襯築窪膚製壓壓積齋窪(廠齋膚淵餘糧鏇窪遞鹽) = 蓋鬱獵鹽餘糧壓願範膚 糧製醖憲膚簾積憲窪鏇 (鹽簾積簾鏇顧壓築餘範, 7.407) 更多 | - | 2017-12-20 | ||
N/A | 15 | 壓鏇觸獵願壓襯範選顧(膚齋簾憲網鬱構餘壓遞) = 齋願鹽壓範繭窪築壓艱 餘鹹壓夢餘遞積獵鬱衊 (顧蓋獵廠觸醖壓簾淵艱, -18 ~ -2) 更多 | - | 2016-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用